Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sugar patterns in blood may foretell liver transplant rejection

NCT ID NCT05866796

NEW Diagnosis Sponsor: University Hospital, Ghent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether a blood test that measures sugar chains on proteins can predict which liver transplant patients will lose their new organ or die within a year. The study enrolls 600 adults who are waiting for or have received a liver transplant. By analyzing blood samples at set times after transplant, the team aims to see if certain sugar patterns signal trouble early, when doctors might still be able to intervene.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a blood test that measures sugar chains on proteins (serum glycomics)
What this could lead to
If validated, this blood test could give doctors an early warning that a liver transplant is failing, allowing them to adjust treatment or plan for a new transplant sooner.
What could go wrong
The test may not predict outcomes as accurately in a larger, more diverse group of patients. It is a prognostic tool, not a treatment, so it cannot prevent graft loss on its own.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients active on the waiting list or undergoing a liver transplantation. All indications for liver transplantations are eligible.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed and dated patient informed consent document * Age ≥ 18 years * Ability to comply with protocol-specified evaluations and scheduled visits * Diagnosis of end-stage liver disease, primary hepatic malignancy meeting the Milan criteria for liver transplantation, or acute hepatic failure * Eligible for liver transplantation and/or active on the waiting list for liver transplantation. Individuals eligible and/or active on the waiting list for multiple organ transplantation including the liver (eg. Combined liver and kidney transplantation, or intestinal transplantation) are also eligible for inclusion. * Consulted the department of Gastroenterology and Hepatology at Ghent University Hospital Exclusion Criteria: \- Transplantation of one or more organs not including the liver

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute hepatic failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute liver failure chronic liver failure liver cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver transplant failure Prognostic biomarkers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xavier Verhelst

    RECRUITING

    Ghent, Flanders, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.